Co-administration of multiple twice daily doses of metformin 1000 mg with sitagliptin 50 mg did not meaningfully alter the pharmacokinetics of sitagliptin and metformin in patients with type 2 diabetes.
Ciclosporin: Co-administration of a single 100-mg oral dose of sitagliptin and a single 600-mg oral dose of ciclosporin increased the AUC and Cmax of sitagliptin by approximately 29% and 68%, respectively. These changes in sitagliptin pharmacokinetics were not considered to be clinically meaningful. The renal clearance of sitagliptin was not meaningfully altered. Therefore, meaningful interactions would not be expected with other p-glycoprotein inhibitors.
Digoxin: Sitagliptin had a small effect on plasma digoxin concentrations. However, patients at risk of digoxin toxicity should be monitored for this when sitagliptin and digoxin are administered concomitantly.